LauraSpringMD

Breast Cancer, Hematologic Oncology

Massachusetts General Hospital

Dr. Spring is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Laura Spring is an oncologist in Boston, MA and is affiliated with Massachusetts General Hospital. She received her medical degree from University of Massachusetts Medical School. She specializes in breast cancer and is active in research.

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2014 - 2017
Brigham and Women's HospitalResidency, Internal Medicine, 2011 - 2014
University of Massachusetts Medical SchoolClass of 2011

ATEMPT 2.0: Adjuvant T-DM1 vs TH Start of enrollment: 2021 Jun 16
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) Start of enrollment: 2020 Dec 16
Recruiting
Phase 2
Roles: Principal Investigator, Contact, Sponsor-Investigator
Sacituzumab Govitecan In TNBC Start of enrollment: 2020 Jul 14
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. Start of enrollment: 2019 Oct 09
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Join now to see all

PubMed

Journal Articles

Effect of Eribulin with or Without Pembrolizumab on Progression-Free Survival for Patients with Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
Sara M Tolaney, Gerburg Wulf, Laura Spring, Beth Overmoyer, Ann H Partridge, Eric P Winer, Ian E Krop, JAMA Oncology
Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer During the Covid-19 Pandemic
Laura Spring, MD, The New England Journal of Medicine
A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer
David T Miyamoto, Aditya Bardia, Lecia V Sequist, Laura M Spring, Daniel A Haber, Mark Kalinich, Clinical Cancer Research

Lectures

Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer.
2019 ASCO Annual Meeting - 6/1/2019
Breast Cancer Index (BCI) and prediction of pathological complete response (pCR) to neoadjuvant chemotherapy in estrogen receptor positive (ER+) breast cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer During the Covid-19 PandemicJuly 2020
Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer During the Covid-19 PandemicJuly 2020
Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer During the Covid-19 PandemicJuly 2020

Adjuvant Chemo Might Not Add Benefit in Breast Cancer Patients Who Have Excellent Response to Neoadjuvant ChemoDecember 5th, 2018
Breast Cancer Symptoms to Look Out ForDecember 7th, 2017
National Breast Cancer Awareness Month: Key Terms You Should KnowOctober 1st, 2017
Join now to see all